ERBB2 and breast cancer: In spite of the lack of survival differences between ILC and IDC in most large datasets, the univariate adverse prognostic effects of ILC phenotype had appeared to be restricted to women with HR and HER2/neu-negative breast cancer, the majority of whom received adjuvant chemotherapy.